【藥品性質提示】 ★LASA藥品：TRA06 【E5】Trajenta DUO複方 (形似) 點擊看LASA藥品外觀比較圖

糖尿病 (DPP4I / Metformin) Type 2 diabetes mellitus

Linagliptin: dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor

1. Hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity) to linagliptin, metformin, or any component of the formulation
2. Renal impairment (eg, serum creatinine 1.5 mg/dL in males or 1.4 mg/dL in females), or abnormal creatinine clearance, which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia
3. Acute or chronic metabolic acidosis including diabetic ketoacidosis

B

Excretion in breast milk unknown/use caution

Common: Diarrhea, decreased appetite, nausea, vomiting, pancreatitis; nasopharyngitis, cough; back pain, headache, pruritus, hypersensitivity
Postmarketing: Severe arthralgia (FDA Safety Alert, Aug 28, 2015)

Initial doses should be based on current dose of linagliptin and metformin

1. eGFR ≥30 to <45 mL/minute/1.73 m²: In patients currently receiving metformin, use with caution, consider dosage reduction (eg, 50% reduction or 50% of maximal dose), monitor renal function every 3 months. Do not initiate therapy in patients with eGFR <45 mL/minute/1.73 m².
2. eGFR <30 mL/minute/1.73 m²: Discontinue use